(XCUR) Exicure, Inc. Business Model Canvas Research

Exicure, Inc. uses collaboration, option, and license deals to fund and grow its SNA pipeline without building every asset in-house. This setup can bring in outside capital and partner expertise while Exicure keeps platform value and shared upside.

• Non-dilutive cash and know-how
• Faster pipeline growth, lower build cost

Exicure, Inc. relies on biotech partnerships to move ideas from translational research into development plans and, if validated, commercialization. In FY2025, the company remained a partnering-led platform, so external scientific ties are central to progress and capital efficiency.

• Supports translational research
• Shapes development planning
• Enables commercialization paths
• Core to a platform model

Exicure, Inc. is using target identification to expand its SNA platform beyond one shot on goal, with current work across 4 areas: pain, hair loss, Huntington’s disease, and Angelman syndrome. That spread helps reduce platform risk and keeps the pipeline tied to multiple clinical paths instead of a single indication.

• 4 current focus areas
• Pain and hair loss
• Huntington’s disease
• Angelman syndrome

Exicure must tightly track patents, licenses, and contract terms because a U.S. patent can last 20 years from filing, and that window drives SNA platform value. Strong IP control also supports partner talks by making field-of-use rights, milestones, and royalty terms easier to price.

• Protect SNA patents and know expiries.
• Track licenses, royalties, and milestones.
• Use clean IP to win partners.

Exicure, Inc.'s scientific and technical know-how in nucleic-acid therapeutics is its core asset: it is needed to design, test, and optimize spherical nucleic acid (SNA) molecules, and to speak credibly with pharma partners. In a capital-light field where R&D success is measured by preclinical fit and partner interest, this expertise drives value.

• Design and optimize SNA molecules
• Support preclinical testing
• Strengthen pharma partner talks

Exicure, Inc. is based in Chicago, Illinois, and that corporate base supports day-to-day operations, management oversight, and partner coordination. It also anchors the Company’s organizational identity, giving Exicure a clear central hub for execution and control.

• Chicago, Illinois: corporate headquarters
• Supports operations and management
• Helps coordinate partners and internal work
• Anchors Exicure, Inc. identity

Exicure and AbbVie are advancing SNA-based hair-loss therapies for a market that affects about 80 million Americans, including roughly 50 million men and 30 million women. With AbbVie’s commercial reach, the program can turn Exicure’s platform science into a real dermatology product, not just a lab asset.

• Large, proven consumer-health demand
• AbbVie adds commercial scale
• SNA science supports pipeline value

Exicure’s partnered platform de-risks R&D by sharing cost, data, and failure risk with collaborators, which can be cheaper than funding every program in-house. The tradeoff is lower direct control, but larger partners can also improve reach and raise the odds of clinical and commercial progress.

• Risk is shared, not borne alone
• Lower internal burn versus solo R&D
• Larger partners can speed market access

Exicure’s long-term scientific support must stay consistent across multi-year biotech programs; drug development often takes 10-15 years, and about 90% of candidates still fail before approval. That makes technical continuity a core part of customer trust and platform credibility, especially when the same collaboration has to survive preclinical work, IND filing, and later-stage updates.

• Keep the same scientific team
• Protect data and method continuity
• Support programs for years, not months

Exicure, Inc. relies on trust in its data quality and execution because, as a small biotech with a specialized platform, it has little room for error and limited commercial scale. When partners believe the science is clean and the team delivers on time, they are more likely to expand program scope, which can matter more than near-term revenue in a platform-led model.

• Trust drives scope expansion.
• Execution quality protects partner confidence.
• Small biotechs need credibility fast.

Exicure, Inc.'s Chicago headquarters anchors business development and partner communication, while management, planning, and admin work stay in one place. That central setup helps keep collaborations active and decisions moving quickly.

• Runs partner outreach from Chicago
• Supports management and planning
• Keeps collaborations coordinated

Exicure, Inc. uses investor and industry communications to explain pipeline updates, financing moves, and partnership status, which matters in biotech where milestones can shift valuation fast. Public updates also help attract new collaborators and holders; Exicure’s recent SEC filings and press releases show how this channel supports visibility when clinical data and capital access are limited.

• Shares pipeline progress clearly
• Signals partnership status fast
• Builds visibility for investors
• Attracts future collaborators

Exicure’s neurology customer segment is the patients who would use successful drugs for pain, Huntington’s disease, and Angelman syndrome. Huntington’s affects about 41,000 people in the U.S. and Angelman syndrome about 1 in 12,000 to 20,000 births, so these are small but high-need groups with few treatment options.

• Neurology patients are the end users.
• Focus: pain, Huntington’s, Angelman syndrome.
• High unmet need, no approved Exicure drug.

Hair-loss patients are a core target for Exicure, Inc., because androgenetic alopecia alone affects about 50 million men and 30 million women in the US. Exicure’s partnered program is built for this segment, and the addressable market is large, recurring, and commercially meaningful as patients often seek long-term treatment.

• ~80 million US hair-loss patients
• Partnered program targets alopecia
• Large, repeat-use market

Exicure, Inc.'s general and administrative expenses are driven by Chicago-based corporate operations, including management, finance, compliance, and administration. This overhead is a fixed cash burden before product sales begin, so G&A stays high relative to revenue in the early stage.

• Chicago corporate overhead
• Management and finance costs
• Compliance and admin spend
• Needed before sales start

Regulatory and development support costs rise as Exicure moves candidates toward clinical testing, because each asset needs IND-enabling work, study design, and FDA-ready documentation. In biotech, IND packages often take 12-18 months to assemble, so this line item usually scales with pipeline depth and stage.

• IND-enabling work comes before first dosing
• Costs climb as candidates advance
• Regulatory prep supports future clinical entry

For Exicure, this cost bucket is tied to future development activity, not just today’s lab work, so spending can step up fast once a program moves from discovery into formal testing.

Milestone-based revenue lets Exicure, Inc. collect payments when a program hits research, regulatory, or clinical goals, so this can be a key cash source for a pre-commercial biotech. These deals are usually lumpy: one trigger can pay out, then revenue can sit at $0 until the next milestone is met.

For investors, the value is in the size and timing of each step-up payment, not steady sales; many biotech deals use milestones in the low millions to tens of millions of dollars per event, often tied to IND, Phase 1/2, or approval steps.

• Triggered by R&D, clinical, and regulatory wins
• Cash flow is irregular, not recurring
• Critical when Company Name has no product sales

Exicure, Inc. can earn future royalties only if partnered products reach market, so this stream is still contingent and currently $0 in reported product royalties. That makes it a high-upside, low-touch revenue line: payments scale with commercial sales, not internal manufacturing.

• Royalties start after market launch
• Revenue rises with partner sales
• Current royalty income: $0